Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Acquired Vitelliform Lesions in Intermediate Age-Related Macular Degeneration: A cross-sectional study
Author Affiliations & Notes
  • Sophiana Maya Michele Lindenberg
    DIRRL, Doheny Eye Institute, Pasadena, California, United States
  • Alireza Mahmoudi
    DIRRL, Doheny Eye Institute, Pasadena, California, United States
    Department of Ophthalmology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Deniz Oncel
    DIRRL, Doheny Eye Institute, Pasadena, California, United States
  • Giulia Corradetti
    DIRRL, Doheny Eye Institute, Pasadena, California, United States
    Department of Ophthalmology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Damla Oncel
    DIRRL, Doheny Eye Institute, Pasadena, California, United States
  • Mehdi Emamverdi
    DIRRL, Doheny Eye Institute, Pasadena, California, United States
    Department of Ophthalmology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Louay Almidani
    DIRRL, Doheny Eye Institute, Pasadena, California, United States
    Retina Consultants of Texas, Houston, Texas, United States
  • Alireza Farahani
    DIRRL, Doheny Eye Institute, Pasadena, California, United States
    Department of Ophthalmology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Yu Wakatsuki
    DIRRL, Doheny Eye Institute, Pasadena, California, United States
  • Ye He
    DIRRL, Doheny Eye Institute, Pasadena, California, United States
    Department of Ophthalmology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Stanley M Saju
    Retina Consultants of Texas, Houston, Texas, United States
  • Charles Clifton Wykoff
    Retina Consultants of Texas, Houston, Texas, United States
    Houston Methodist Hospital, Houston, Texas, United States
  • David Sarraf
    Department of Ophthalmology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • K. Bailey Freund
    Vitreous Retina Macula Consultants of New York, New York, New York, United States
    Department of Ophthalmology, New York University Grossman School of Medicine, New York, New York, United States
  • SriniVas R Sadda
    DIRRL, Doheny Eye Institute, Pasadena, California, United States
    Department of Ophthalmology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Sophiana Lindenberg None; Alireza Mahmoudi None; Deniz Oncel None; Giulia Corradetti Nidek, Code R (Recipient); Damla Oncel None; Mehdi Emamverdi None; Louay Almidani None; Alireza Farahani None; Yu Wakatsuki None; Ye He None; Stanley Saju None; Charles Wykoff 4DMT, Abbvie, Adverum, Aerie, AGTC, Alcon, Annexon, Apellis, Arrowhead, Ascidian, Bausch + Lomb, Bayer, Boehringer Ingelheim, Cholgene, Clearside, Curacle, Eyebiotech, EyePoint, Foresite, Foresite, Frontera, Genentech, Gyroscope, IVERIC Bio, Janssen, Kato, Kiora, Kodiak, Merck, Nanoscope, Neurotech, NGM, Notal Vision, Novartis, Ocular Therapeutix, Ocuphire, OcuTerra, ONL, Opthea, Oxular, PerceiveBio, Ray, RecensMedical, Regeneron, RegenXBio, Resonance, Roche, Sandoz, Sanofi, SciNeuro, Stealth, Surrozen, Suzhou Raymon, Palatin, THEA, Therini, Valo, Code C (Consultant/Contractor), ONL, PolyPhotonix, RecensMedical, TissueGen, Visgenx, Vitranu, Code O (Owner), 4DMT, Adverum, AffaMed, Alexion, Alimera, Allgenesis, Amgen, Annexin, Annexon, Apellis, Asclepix, Bayer, Boehringer Ingelheim, Chengdu Kanghong, Clearside, Curacle, Eyebiotech, EyePoint, Genentech, Gyroscope, IONIS, iRENIX, IVERIC Bio, Janssen, Kodiak, LMRI, McMaster University, Nanoscope, Neurotech, NGM, Novartis, Ocular Therapeutix, Ocuphire, OcuTerra, OliX, Opthea, Oxurion, Oxular, Oyster Point, PerceiveBio, Regeneron, RegenXBio, Rezolute, Roche, SamChunDang, Sandoz, Shanghai Henlius, UNITY, Verily,, Code R (Recipient), ONL, PolyPhotonix, RecensMedical, TissueGen, Visgenx, Vitranu, Code S (non-remunerative); David Sarraf amgen inc,bayer healthcare, genentech, heidelberg engineering, novartis pharmaceuticals corporation, optovue inc, regeneron pharmaceuticals, topcon corporation, Code C (Consultant/Contractor), amgen inc,bayer healthcare, genentech, heidelberg engineering, novartis pharmaceuticals corporation, optovue inc, regeneron pharmaceuticals, Code F (Financial Support); K. Bailey Freund Carl Zeiss Meditec, Heidelberg Engineering, Nidek, Inc., Novartis Pharma AG, Regeneron Pharmaceuticals, Inc., Code C (Consultant/Contractor); SriniVas Sadda 4DMT, Abbvie, Alexion, Allergan Inc., Alnylam Pharmaceuticals, Amgen Inc., Apellis Pharmaceuticals, Inc., Astellas, Bayer Healthcare Pharmaceuticals, Biogen MA Inc., Boehringer Ingelheim, Carl Zeiss Meditec, Catalyst Pharmaceuticals Inc., Centervue Inc., GENENTECH, Gyroscope Therapeutics, Heidelberg Engineering, Hoffman La Roche, Ltd., Iveric Bio, Janssen Pharmaceuticals Inc., Nanoscope, Notal Vision Inc., Novartis Pharma AG, Optos Inc., Oxurion/Thrombogenics, Oyster Point Pharma, Regeneron Pharmaceuticals Inc., Samsung Bioepis, Topcon Medical Systems Inc. , Code C (Consultant/Contractor), Carl Zeiss Meditec, Heidelberg Engineering, Optos Inc., Nidek, Topcon, Centervue, Code F (Financial Support), Carl Zeiss Meditec, Heidelberg Engineering, Nidek Incorporated, Novartis Pharma AG, Topcon Medical Systems Inc., Code R (Recipient)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2308. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sophiana Maya Michele Lindenberg, Alireza Mahmoudi, Deniz Oncel, Giulia Corradetti, Damla Oncel, Mehdi Emamverdi, Louay Almidani, Alireza Farahani, Yu Wakatsuki, Ye He, Stanley M Saju, Charles Clifton Wykoff, David Sarraf, K. Bailey Freund, SriniVas R Sadda; Acquired Vitelliform Lesions in Intermediate Age-Related Macular Degeneration: A cross-sectional study. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2308.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The study aims to define the characteristics of acquired vitelliform lesions (AVL) in patients with intermediate age-related macular degeneration (iAMD).

Methods : In this retrospective cross-sectional case-control study, we included optical coherence tomography (OCT) volume scan data from 217 eyes (168 patients) with AVL(s), and an equivalent number of control patients with iAMD without AVL (matched for age and gender). The OCT scans were evaluated for qualitative and quantitative parameters at both the eye and lesion level. Eye level parameters included the presence of: hyporeflective core drusen (hCD), intraretinal hyperreflective foci (IHRF), subretinal drusenoid deposits (SDD), pachyvessels in the macula, central retinal thickness (CRT), and central choroidal thickness (CCT). Lesion level qualitative parameters included the presence of: ellipsoid zone (EZ) and external limiting membrane (ELM) disruption overlying AVL, IHRF overlying AVL, AVL overlying drusen, pachyvessels under AVL, a solid core inside AVL, and the location of AVL. Lesion level quantitative characteristics included AVL height and width, AVL distance from the fovea, and sub-AVL choroidal thickness. Spearman's correlation analysis was performed to explore relationships among various AVL characteristics.

Results : In the comparison between the case and control groups (each with 217 eyes from 168 patients), the frequency of IHRF (case: 49.3% vs control: 26.3%) and pachyvessels in the macular region (37.3% vs 6.9%) was significantly higher in the case group, while CCT (166.1 ± 62 µm vs 206 ± 45 µm) was thinner in the case group. AVL located over drusen, with overlying IHRF, or situated subfoveally, and AVL lesions with EZ disruption, were found to have a greater lesion height and width compared to AVL lesions lacking these characteristics (P-value < 0.001 for all). Additionally, a significant negative correlation was observed between distance from the fovea and AVL height (Spearman's rho: -0.19, P = 0.002) and width (Spearman’s rho: -0.30, P=0.001).

Conclusions : This study represents the largest reported cohort of AVL lesions associated with iAMD. Novel findings include the higher frequency of pachyvessels despite a thinner choroid in these eyes, as well as a greater height and width of AVLs closer to the foveal center. These findings may offer insights into pathophysiologic mechansims underlying the development of AVLs.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×